A detailed history of Bank Of America Corp transactions in Axonics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 200,934 shares of AXNX stock, worth $14.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
200,934
Previous 120,490 66.76%
Holding current value
$14.2 Million
Previous $8.31 Million 62.55%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$66.47 - $69.65 $5.35 Million - $5.6 Million
80,444 Added 66.76%
200,934 $13.5 Million
Q1 2024

May 15, 2024

BUY
$56.67 - $69.36 $59,956 - $73,382
1,058 Added 0.89%
120,490 $8.31 Million
Q4 2023

Feb 14, 2024

BUY
$49.38 - $63.75 $1.04 Million - $1.34 Million
21,034 Added 21.38%
119,432 $7.43 Million
Q2 2023

Aug 14, 2023

SELL
$47.99 - $60.21 $24.9 Million - $31.3 Million
-519,539 Reduced 84.08%
98,398 $4.97 Million
Q1 2023

May 12, 2023

BUY
$52.6 - $67.34 $24 Million - $30.8 Million
456,659 Added 283.15%
617,937 $33.7 Million
Q4 2022

Feb 10, 2023

BUY
$59.56 - $76.6 $3.07 Million - $3.94 Million
51,464 Added 46.86%
161,278 $10.1 Million
Q3 2022

Nov 14, 2022

BUY
$57.96 - $78.12 $691,404 - $931,893
11,929 Added 12.19%
109,814 $7.74 Million
Q2 2022

Aug 12, 2022

SELL
$39.5 - $64.42 $640,216 - $1.04 Million
-16,208 Reduced 14.21%
97,885 $5.55 Million
Q1 2022

May 16, 2022

SELL
$43.74 - $62.76 $369,034 - $529,506
-8,437 Reduced 6.89%
114,093 $7.14 Million
Q4 2021

Feb 08, 2022

SELL
$50.01 - $73.35 $681,486 - $999,540
-13,627 Reduced 10.01%
122,530 $6.86 Million
Q3 2021

Nov 15, 2021

SELL
$59.21 - $78.66 $88,400 - $117,439
-1,493 Reduced 1.08%
136,157 $8.86 Million
Q2 2021

Sep 13, 2021

BUY
$51.39 - $66.9 $7.07 Million - $9.21 Million
137,650 New
137,650 $8.73 Million

Others Institutions Holding AXNX

About Axonics, Inc.


  • Ticker AXNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 49,123,600
  • Market Cap $3.46B
  • Description
  • Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention...
More about AXNX
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.